The stock looks cheap, but appearances can be deceiving.

Don't call Recursion Pharmaceuticals (NASDAQ: RXRX) a biotech company. Its management prefers the term "TechBio." While many have been skeptical about TechBio in the past, the reception is changing ...

Chris Gibson, PhD, Recursion’s co-founder and CEO, discusses exclusively with GEN Edge his company’s ambitious plans to develop 100 pipeline candidates in roughly a decade, the savings in money and ...

The concept of a meme stock was born about five years ago. It refers to a publicly traded company that gains substantial market value practically overnight (sometimes literally) due to significant ...

We believe that Recursion RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is likely to beat expectations when it reports second-quarter 2024 results. The ...

Unmet clinical needs often serve as the fundamental driving force behind drug discovery programs. During lead discovery, an intensive search ensues to find a drug-like small molecule or biological ...

Recursion Pharmaceuticals announces a workforce reduction of approximately 20%. The Nvidia-backed company expects the move to extend its cash runway into the fourth quarter of 2027. Get more ...

Hi, everyone. Let's get started. Welcome to the 44th Annual JPMorgan Healthcare Conference. My name is Priyanka Grover, and I'm part of the JPMorgan Biotech team. Today, our next presenting company is ...

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...